Sydney, Australia, 19th-20th September 2020: DermaSensor, the medical device company that enables healthcare professionals to efficiently check for skin cancer, is joining forces with HealthCert, the number one professional education provider for skin cancer management and treatment to demonstrate its world-first technology at HealthCert at the Convention and Exhibition Centre in Sydney.
HealthCert International is a global organisation dedicated to achieving better patient outcomes through comprehensive GP education and universal access to diagnosis and treatment. It provides medical and patient education and runs skin cancer centres where patients can access head-to-toe skin checks, lesion diagnosis and treatment, and TeleDermatology to enable quick diagnosis and treatment recommendations on skin cancer and general dermatology cases.
Kevin Scrimshaw, Commercial Director, ANZ and Martina Clark Territory Business Manager, VIC Australia from the DermaSensor team will showcase the DermaSensor device, a revolutionary, world-first technology, designed to augment clinician decision making by providing accurate differentiation between malignant and benign skin lesions.
“DermaSensor’s technology helps clinicians quickly and effectively check for skin cancer,” explains Kevin. “The device can assess a lesion in under 30 seconds using optical spectroscopy and machine learning technology and will become a standard tool of the trade in primary care,” he says.
This exciting breakthrough was achieved using Elastic Scattering Spectroscopy. This technology pioneered at Boston University and University College London. It uses light to evaluate cellular and subcellular structures of the skin.
A recent clinical study found that DermaSensor achieved a sensitivity of 100 percent for detecting melanoma and 94 percent for detecting nonmelanoma skin cancer.
The device is undergoing FDA and TGA approval and is expected to be available in Australia in late-2020. The DermaSensor device is low-cost and easy-to-use. It enables healthcare providers and patients to receive fast and accurate skin lesion assessments to ultimately improve outcomes for patients with skin cancer.
“The handheld DermaSensor device takes five quick recordings via non-invasive sub-cellular scans. This provides an immediate, objective result that’s typically more accurate than visual assessment alone,” Kevin explains.
Its speed and ease of use improves workflow by extending lesion identification and evaluation to trained team members. Patients can expect to experience fewer unnecessary complications or side effects and medical practitioners may spend less time on lengthy procedures.